Search

Displaying results 4651 - 4660 of 7897 in total
  1. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The oral polio vaccine (OPV) is a live attenuated vaccine containing a mixture of one or more strains of poliovirus serotypes. … After administration, OPV strains extensively multiply in the intestinal tract, becoming widely spread in the community to immunize a sizable proportion of those unvaccinated in the population[A220163]

  2. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. … CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of

  3. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). … ," as well as notification of health care providers.

  4. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [L53203] It has been under investigation in humans since at least 2012. … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.

  5. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix is a synthetically derived thyroid hormone replacement preparation. … It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight.

  6. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  7. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the

  8. Drug

    Kinetin

    go.drugbank.com/drugs/DB11336
    Approved

    While kinetin is used in tissue cultures to produce new plants, it is also found in cosmetic products as an anti-aging agents. … Kinetin is a cytokinin which are plant hormones promotes cell division and plant growth. It was shown to naturally exist in DNA of organisms including humans and various plants.

  9. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. … Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

  10. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.